10.02.09
Madeira Therapeutics Participates as a Keynote Speaker at the 7th Annual BioNetwork Conference in California
(LEAWOOD, KS; October 2, 2009) – Peter Joiner, president and chief executive officer of Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, will serve as a keynote speaker and panelist at the 7th Annual BioNetwork Conference at the Ritz Carlton in Laguna Niguel, California, on October 5-7, 2009.
Mr. Joiner was invited as a keynote speaker for the conference, addressing the topic “The Need for FDA Approved Pediatric Labeled Medication,” held October 7, from 9:15-9:55 a.m. Currently, 70% of the drugs prescribed for children are not approved by the FDA. Mr. Joiner will address this severe need with a case based on the surrounding healthcare concerns in pediatrics today, such as childhood obesity.
Mr. Joiner is also part of a panel discussion focused on “Survival Strategies in a Down Economy: How Small Biotechs Are Remaining Strong.” Mr. Joiner will be accompanied by three other individuals to discuss methods and tactics applicable to sustaining business in the industry today. The topic of partnering strategies is particularly relevant to Madeira Therapeutics as they look to acquire additional investors to support upcoming clinical trials on an up-and-coming drug: the first ever liquid preparation of a statin for children and the elderly.
BioNetwork 2009 will host over 200 industry experts from pharma and biotech companies sharing best practices, solutions and insight into successful partnering strategies. For more information, visit http://www.wbresearch.com/bionetworkwest/.
About Madeira Therapeutics
Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals who serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA’s 505(b)(2) approval method, which relies in part on the regulatory agency’s findings for a drug previously approved for adults, thereby shortcutting IND approval by years and saving tens of millions of dollars in development costs. The company’s lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The company’s second product is MT-003 for acute pain relief. For more information, please visit http://www.madeiratherapeutics.com/.
